Warren Buffett's Successor Greg Abel Just Broke This 13-Quarter Streak at Berkshire Hathaway. Could This Be a Turning Point for the Stock Market?

Berkshire Hathaway ended Warren Buffett’s 13-quarter streak of net equity selling in Q1 2026, with nearly $16 billion of stock purchases and a $9.7 billion OxyChem acquisition offsetting more than $24 billion of equity sales. Greg Abel also resumed buybacks, repurchasing just $238 million despite Berkshire’s price-to-book falling to a two-year low, suggesting continued caution about valuations. The article frames the capital deployment as a potential sign of better opportunities, but not a broad shift to aggressive buying.

Analysis

The key signal is not that Berkshire finally bought something; it is that even after a multi-quarter cash build, management still prefers a large, identifiable asset over broad equity exposure. That implies the hurdle rate for public stocks remains high, so the marginal dollar is still being reserved for situations with control rights, financing flexibility, or asset-backed downside protection. In practice, that is a warning that the market’s breadth may still be too rich for a capital allocator who can absorb billions at a time.

The OXYChem purchase matters more than the equity tally because it suggests Berkshire is still willing to pay up for cash-generative industrial assets when the strategic fit is clear. That creates a relative winner in OXY: the divestiture de-risks the balance sheet, likely improves capital allocation optics, and could support the stock even if oil stays range-bound. The second-order loser is the broader public-equity complex: if Berkshire is only selectively buying while still trimming other holdings, that reinforces the idea that large-cap quality has become crowded and that future returns may be more idiosyncratic than index-driven.

The contrarian miss is that Berkshire’s behavior may be driven less by a macro call and more by portfolio mechanics. With massive cash, the firm cannot deploy meaningfully unless opportunities are huge, so a lack of buying in most quarters does not necessarily mean the market is unattractive for smaller capital pools. That is especially true in underfollowed areas where Berkshire has limited expertise; the opportunity set for active investors is likely better in smaller names and special situations than in the mega-cap basket.

Catalyst-wise, the next 1-2 quarters matter: if buybacks stay anemic despite lower prices, the market should interpret that as a genuine valuation ceiling from management, not a temporary pause. Conversely, a second large asset purchase or sustained repurchases would signal that the floor on attractive opportunities has moved up. Until then, Berkshire’s own capital allocation is a better contrarian warning than a broad buy signal.

Key Decisions for Investors

• Long OXY vs. short XLE for 3-6 months: OXY has a cleaner catalyst from asset monetization and balance-sheet optionality; the short basket hedges crude beta while expressing relative value.
• Reduce exposure to BRK.B on strength over the next 1-2 quarters: if buybacks remain minimal, the stock likely trades as a high-quality cash hoard with limited near-term catalyst rather than a capital deployment story.
• Rotate toward smaller-cap special situations and spin-offs over mega-cap quality over the next 6-12 months: Berkshire’s behavior argues the easy money in obvious large-cap value is gone, while dispersion should stay high.
• Consider a call spread in OXY 6-9 months out if oil stays range-bound: the market may re-rate the stock on capital-return/asset-sale optics even without a commodity breakout.
• Avoid extrapolating Berkshire’s public-equity caution into a broad short on equities: use it as a valuation filter, not a market-timing signal; pair any bearish index view with longs in under-owned, cash-generative names.